From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.
wendy_avl said:Worth knowing that eGFR estimates depend on creatinine, and creatinine depends on muscle mass.
Coming at wendy_avl’s question from a different direction. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
One concrete data point for the thread. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after wendy_avl’s answer:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.